Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (vol 40, pg 3065, 2022).

被引：0
|
作者：
Shen, Lin
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 04期
关键词：
D O I：
10.1200/JCO.23.02629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：486 / 486
页数：1
相关论文
共 50 条
  • [31] Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
    Jianming Xu
    Yi Li
    Qingxia Fan
    Yongqian Shu
    Lei Yang
    Tongjian Cui
    Kangsheng Gu
    Min Tao
    Xiuwen Wang
    Chengxu Cui
    Nong Xu
    Juxiang Xiao
    Quanli Gao
    Yunpeng Liu
    Tao Zhang
    Yuxian Bai
    Wei Li
    Yiping Zhang
    Guanghai Dai
    Dong Ma
    Jingdong Zhang
    Chunmei Bai
    Yunchao Huang
    Wangjun Liao
    Lin Wu
    Xi Chen
    Yan Yang
    Junye Wang
    Shoujian Ji
    Hui Zhou
    Yan Wang
    Zhuo Ma
    Yanqi Wang
    Bo Peng
    Jiya Sun
    Christoph Mancao
    Nature Communications, 13
  • [32] PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
    Zhu, Xinxin
    Shanzhou, Qiyue
    Li, Danyang
    Pang, Xuezhou
    Ma, Daiyuan
    BMC CANCER, 2021, 21 (01)
  • [33] PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
    Xinxin Zhu
    Qiyue Shanzhou
    Danyang Li
    Xuezhou Pang
    Daiyuan Ma
    BMC Cancer, 21
  • [34] Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Yang, Fan
    Fu, Yu
    Kumar, Arun
    Chen, Mingsheng
    Si, Lei
    Rojanasarot, Sirikan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (15)
  • [35] Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Lin, Ying-Tao
    Chen, Ying
    Liu, Tian-Xiu
    Kuang, Fang
    Huang, Ping
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8219 - 8230
  • [36] COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS CHEMOTHERAPY FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) AS THE SECOND-LINE TREATMENT AMONG THE CHINESE POPULATION
    Wang, Y.
    Huang, Y.
    Shao, H.
    VALUE IN HEALTH, 2021, 24 : S32 - S32
  • [37] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
    Xu, Jianming
    Kato, Ken
    Raymond, Eric
    Hubner, Richard A.
    Shu, Yongqian
    Pan, Yueyin
    Park, Sook Ryun
    Ping, Lu
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Kojima, Takashi
    Gotovkin, Evgeny
    Ishihara, Ryu
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Lin, Chen -Yuan
    Wang, Lei
    Shi, Jingwen
    Li, Liyun
    Yoon, Harry H.
    LANCET ONCOLOGY, 2023, 24 (05): : 483 - 495
  • [38] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
    Hubner, R.
    Xu, J.
    Kato, K.
    Raymond, E.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S. R.
    Kojima, T.
    Lin, C-Y.
    Gotovkin, E.
    Wyrwicz, L. S.
    Ishihara, R.
    Wu, H.
    Peng, Y.
    Wang, L.
    Li, L.
    Yoon, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S853 - S853
  • [39] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
  • [40] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Liu, Yanhong
    Shao, Rong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345